A variety of compounds with different targets are currently being tested in Phase II studies for their ability to reduce the progression of Parkinson’s Disease (PD). Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, outlines some of the key targets under investigation, based on insights from studies of PD pathophysiology. These include alpha-synuclein, the inflammasome, LRKK2 and GBA. It is hoped that combinatory approaches could significantly alter the disease trajectory in patients with PD, by tackling the underlying drivers of disease from several angles. Intervening earlier in the disease course is also a key focus of current research efforts. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Dr Pagano is a full-time employee and shareholder at F. Hoffmann – La Roche Ldt.